-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the past four decades, non-alcoholic fatty liver disease ( NAFLD ) has become the most common chronic liver disease.
，（NAFLD）。NAFLD25%NAFLD25%，。，。，。10%NAFLD，。
，NAFLD，、。GUT——51，71%，。
Due to its high prevalence, NAFLD is now the fastest growing cause of liver-related mortality in the world, and has become an important cause of end-stage liver disease, primary liver cancer, and liver transplantation.Morbidity and disease burden
Incidence and burden of disease Incidence and burden of diseaseThe incidence of NAFLD ranges from 13-5% in Africa to 31-8 % in the Middle East , mainly related to differences in caloric intake, physical activity, body fat distribution, socioeconomic status, and genetic makeup.
The incidence of NAFLD ranges from 13-5% in Africa to 31-8 % in the Middle East , mainly related to differences in caloric intake, physical activity, body fat distribution, socioeconomic status, and genetic makeup.
The relationship between NAFLD and all-cause mortality is unclear.
Natural evolution of disease
Natural evolution of disease natural evolution ofdiseaseAn assessment paired liver biopsy samples NAFLD meta-analysis of studies found, NASH patients with fibrosis average 7.
An assessment paired liver biopsy samples NAFLD meta-analysis of studies found, NASH patients with fibrosis average 7.
Disease risk stratification and severity assessment Disease risk stratification and severity assessment
NAFLD is most often diagnosed by imaging .
NAFLD is most often diagnosed by imaging .
NAFLD histological and radiological evaluation
NAFLD histological and radiological evaluationT2DM is associated with advanced fibrosis, liver cirrhosis-related complications, and liver disease mortality increased by more than 2 times.
T2DM is associated with advanced fibrosis, liver cirrhosis-related complications and increased mortality of liver disease 2 T2DM is associated with advanced fibrosis, liver cirrhosis-related complications, and increased mortality of liver disease by more than 2 times.
How to slow the progression of the disease How to slow the progression of the disease
Because metabolic syndromes such as T2DM and obesity seriously affect the progression of NAFLD , obesity can affect the occurrence of T2DM .
Because metabolic syndromes such as T2DM and obesity seriously affect the progression of NAFLD , obesity can affect the occurrence of T2DM .
The interaction between multiple pathways and different organs affects the pathogenesis of NAFLD
The interaction between multiple pathways and different organs affects the pathogenesis of NAFLDIn summary, the presence of fibrosis is a key prognostic marker for NAFLD and overall mortality.
In summary, the presence of fibrosis is a key prognostic marker for NAFLD and overall mortality.
references:
references:Non-alcoholic fatty liver disease.
Non-alcoholic fatty liver disease.
Published: April 21, 2021 DOI: https://doi.
org/10.
1016/S0140-6736(20)32511-3.
Non-alcoholic fatty liver disease.
Leave a message here
